FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2990830108> ?p ?o ?g. }

• W2990830108 endingPage "913" @default.
• W2990830108 startingPage "913" @default.
• W2990830108 abstract "Genomic studies of myeloid malignancies (MM), including acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN) and myelodysplasia (MDS), identified mutations with different allele frequencies. Recent studies of clonal hematopoiesis (CH) discovered a subset of MM disease alleles, while other alleles are only observed in overt MM. These observations suggest an important pathogenetic role for the chronology of mutational acquisition. Although bulk sequencing informs prognostication, it cannot distinguish which mutations occur in the same clone and cannot offer definitive evidence of mutational order. Delineation of clonal architecture at the single cell level is key to understanding how the sequential/parallel acquisition of somatic mutations contributes to myeloid transformation. In order to elucidate the clonal structure of MM, we designed a custom single cell 109 amplicon panel of the most frequently mutated amplicons in 50 MM genes using the Mission Bio Tapestri v2 platform. Viable cells were sorted from 90 samples from 78 patients with CH, AML, and MPN/post-MPN AML followed by single cell amplification/sequencing. Mutation calls were filtered based on read depth, quality, and alleles genotyped per cell. We reconstructed a random distribution of clones by permuting genotype calls across cells and generated empirical p values for each clone. To identify dominant clones, we used a Poisson test to determine clones were significantly enriched compared to the mean clone size. Clones with significant p-values (p &lt;0.05) were used to generate plots of clonal architecture of each sample (Figure 1A). Despite significant clonal complexity, the majority of MM patients (80%;72/90) present with one (51/90; 56.7%) or two (21/90; 23.3%) dominant clones. These data show there are specific genotypic combinations which lead to clonal dominance with increased fitness relative to other clones and/or suppression of minor clones by dominant clone(s). We next investigated whether specific molecularly defined AML subtypes had increased clonal complexity. FLT3-ITD mutant AML samples had a significantly greater number of clones (p &lt; 0.002) compared to AML samples with multiple epigenetic modifier mutations. Similar findings were not observed when comparing AML samples with epigenetic mutations to RAS pathway mutant samples. We next investigated whether specific mutations were likely to co-occur/be mutually exclusive at a single cell level. We observed evidence of oligoclonality in CH, including parallel acquisition of DNMT3A mutations and clones with multiple mutations in the absence of progression to MM. By contrast, in MM the dominant clone(s) almost always harbored multiple epigenetic modifier mutations, suggesting cooperative epigenetic remodeling in myeloid transformation. Mutations in signaling effectors (FLT3-ITD/TKD; RAS/RAS) were mutually exclusive. We observed distinct FLT3-mutant clones in FLT3-mutant AML patients and parallel acquisition of different RAS pathway mutations. We used this data to develop clonal architecture trees in each patient, giving us a definitive picture of mutational acquisition and transformation at a single cell level. We calculated a Shannon diversity score and observed an increase in clonal complexity with disease evolution; CH samples had the lowest clonal diversity and FLT3-ITD AML patients the highest clonal diversity (Figure 1B). We extended our findings by combining cell surface marker assessment and single cell mutational analysis. Patient samples were stained with an antibody cocktail of 6 oligo-conjugated antibodies with barcode tags prior to single cell sequencing, which allowed simultaneous acquisition of single cell immunophenotypic and genotypic data. This allows us to identify distinct populations of stem/progenitor cells with distinct clonal/mutational repertoires (Figure 1C). Additional data will be presented with this novel approach, which allows us to combine an assessment of stem/progenitor cell frequency with genetic data. This includes studies of CD34+ and CD34- AML, which show striking differences in mutational representation in different stem/progenitor compartments. In summary, our studies of clonal architecture at a single cell level provide us novel insights into the pathogenesis of myeloid transformation and give us new insights into how clonal complexity contributes to disease progression. Disclosures Ooi: Mission Bio: Employment, Equity Ownership. Mendez:Mission Bio: Employment, Equity Ownership. Carroll:Janssen Pharmaceuticals: Consultancy; Incyte: Research Funding; Astellas Pharmaceuticals: Research Funding. Papaemmanuil:Celgene: Research Funding. Viny:Mission Bio: Other: Sponsored travel; Hematology News: Membership on an entity's Board of Directors or advisory committees. Levine:Roche: Consultancy, Research Funding; Amgen: Honoraria; Imago Biosciences: Membership on an entity's Board of Directors or advisory committees; Isoplexis: Membership on an entity's Board of Directors or advisory committees; Qiagen: Membership on an entity's Board of Directors or advisory committees; C4 Therapeutics: Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy; Prelude Therapeutics: Research Funding; Loxo: Membership on an entity's Board of Directors or advisory committees; Lilly: Honoraria; Gilead: Consultancy; Celgene: Consultancy, Research Funding." @default.
• W2990830108 created "2019-12-05" @default.
• W2990830108 creator A5002221600 @default.
• W2990830108 creator A5013778834 @default.
• W2990830108 creator A5025660159 @default.
• W2990830108 creator A5029793636 @default.
• W2990830108 creator A5032477226 @default.
• W2990830108 creator A5035097079 @default.
• W2990830108 creator A5043291968 @default.
• W2990830108 creator A5044518913 @default.
• W2990830108 creator A5046282818 @default.
• W2990830108 creator A5050068696 @default.
• W2990830108 creator A5053292642 @default.
• W2990830108 creator A5074326774 @default.
• W2990830108 creator A5074883700 @default.
• W2990830108 creator A5077331342 @default.
• W2990830108 creator A5089512427 @default.
• W2990830108 date "2019-11-13" @default.
• W2990830108 modified "2023-10-01" @default.
• W2990830108 title "Single Cell DNA Sequencing Identifies Combinatorial Mutation Patterns and Clonal Architecture in Myeloid Malignancies" @default.
• W2990830108 doi "https://doi.org/10.1182/blood-2019-128763" @default.
• W2990830108 hasPublicationYear "2019" @default.
• W2990830108 type Work @default.
• W2990830108 sameAs 2990830108 @default.
• W2990830108 citedByCount "1" @default.
• W2990830108 countsByYear W29908301082020 @default.
• W2990830108 crossrefType "journal-article" @default.
• W2990830108 hasAuthorship W2990830108A5002221600 @default.
• W2990830108 hasAuthorship W2990830108A5013778834 @default.
• W2990830108 hasAuthorship W2990830108A5025660159 @default.
• W2990830108 hasAuthorship W2990830108A5029793636 @default.
• W2990830108 hasAuthorship W2990830108A5032477226 @default.
• W2990830108 hasAuthorship W2990830108A5035097079 @default.
• W2990830108 hasAuthorship W2990830108A5043291968 @default.
• W2990830108 hasAuthorship W2990830108A5044518913 @default.
• W2990830108 hasAuthorship W2990830108A5046282818 @default.
• W2990830108 hasAuthorship W2990830108A5050068696 @default.
• W2990830108 hasAuthorship W2990830108A5053292642 @default.
• W2990830108 hasAuthorship W2990830108A5074326774 @default.
• W2990830108 hasAuthorship W2990830108A5074883700 @default.
• W2990830108 hasAuthorship W2990830108A5077331342 @default.
• W2990830108 hasAuthorship W2990830108A5089512427 @default.
• W2990830108 hasConcept C104317684 @default.
• W2990830108 hasConcept C113968399 @default.
• W2990830108 hasConcept C135763542 @default.
• W2990830108 hasConcept C180754005 @default.
• W2990830108 hasConcept C2778729363 @default.
• W2990830108 hasConcept C2779282312 @default.
• W2990830108 hasConcept C49105822 @default.
• W2990830108 hasConcept C501734568 @default.
• W2990830108 hasConcept C502942594 @default.
• W2990830108 hasConcept C54355233 @default.
• W2990830108 hasConcept C81089528 @default.
• W2990830108 hasConcept C8185291 @default.
• W2990830108 hasConcept C86803240 @default.
• W2990830108 hasConceptScore W2990830108C104317684 @default.
• W2990830108 hasConceptScore W2990830108C113968399 @default.
• W2990830108 hasConceptScore W2990830108C135763542 @default.
• W2990830108 hasConceptScore W2990830108C180754005 @default.
• W2990830108 hasConceptScore W2990830108C2778729363 @default.
• W2990830108 hasConceptScore W2990830108C2779282312 @default.
• W2990830108 hasConceptScore W2990830108C49105822 @default.
• W2990830108 hasConceptScore W2990830108C501734568 @default.
• W2990830108 hasConceptScore W2990830108C502942594 @default.
• W2990830108 hasConceptScore W2990830108C54355233 @default.
• W2990830108 hasConceptScore W2990830108C81089528 @default.
• W2990830108 hasConceptScore W2990830108C8185291 @default.
• W2990830108 hasConceptScore W2990830108C86803240 @default.
• W2990830108 hasIssue "Supplement_1" @default.
• W2990830108 hasLocation W29908301081 @default.
• W2990830108 hasOpenAccess W2990830108 @default.
• W2990830108 hasPrimaryLocation W29908301081 @default.
• W2990830108 hasRelatedWork W2050477487 @default.
• W2990830108 hasRelatedWork W2057739827 @default.
• W2990830108 hasRelatedWork W2090075310 @default.
• W2990830108 hasRelatedWork W2223919059 @default.
• W2990830108 hasRelatedWork W2551446388 @default.
• W2990830108 hasRelatedWork W2792120975 @default.
• W2990830108 hasRelatedWork W2800409441 @default.
• W2990830108 hasRelatedWork W2990830108 @default.
• W2990830108 hasRelatedWork W3161453313 @default.
• W2990830108 hasRelatedWork W4318208145 @default.
• W2990830108 hasVolume "134" @default.
• W2990830108 isParatext "false" @default.
• W2990830108 isRetracted "false" @default.
• W2990830108 magId "2990830108" @default.
• W2990830108 workType "article" @default.